Other ICR Research
Recent submissions
-
Systemic biomarkers of immune response in locally-advanced human papillomavirus malignancies treated with radical chemoradiation
(Institute of Cancer Research (University Of London), 2024-02-19)Human papillomavirus (HPV)-driven malignancies exhibit viral oncogenic proteins that act as tumour-specific antigens, making them suitable candidates for monitoring the adaptive immune response during treatment. Chemoradiation ... -
An alternative NURF complex sustains acute myeloid leukemia by regulating the accessibility of insulator regions.
(WILEY, 2023-12-11)Efficient treatment of acute myeloid leukemia (AML) patients remains a challenge despite recent therapeutic advances. Here, using a CRISPRi screen targeting chromatin factors, we identified the nucleosome-remodeling factor ... -
The comprehensive English National Lynch Syndrome Registry: development and description of a new genomics data resource.
(Elsevier BV, 2024-03-01)BACKGROUND: Lynch Syndrome (LS) is a cancer predisposition syndrome caused by constitutional pathogenic variants in the mismatch repair (MMR) genes. To date, fragmentation of clinical and genomic data has restricted ... -
ELM-the Eukaryotic Linear Motif resource-2024 update.
(OXFORD UNIV PRESS, 2024-01-05)Short Linear Motifs (SLiMs) are the smallest structural and functional components of modular eukaryotic proteins. They are also the most abundant, especially when considering post-translational modifications. As well as ... -
Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults.
(NATURE PORTFOLIO, 2023-12-01)Over one million European children undergo computed tomography (CT) scans annually. Although moderate- to high-dose ionizing radiation exposure is an established risk factor for hematological malignancies, risks at CT ... -
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
(American Association for Cancer Research (AACR), 2024-01-05)PURPOSE: Early results from the phase II MEDIOLA study (NCT02734004) in germline BRCA1- and/or BRCA2-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) showed promising efficacy and safety with olaparib ... -
Radical resection of large metastatic non-functioning pancreatic neuroendocrine carcinoma complicated by splenic vein thrombosis and sinistral portal hypertension.
(Elsevier BV, 2021-04-01)INTRODUCTION AND IMPORTANCE: There are limited reports in the literature of radical surgical resection for pancreatic neuroendocrine carcinoma (PNEC). In patients with non-functioning PNEC (NF-PNEC) within the tail of the ... -
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
(Elsevier BV, 2023-12-08) -
Phosphatase specificity principles uncovered by MRBLE:Dephos and global substrate identification.
(WILEY, 2023-12-06)Phosphoprotein phosphatases (PPPs) regulate major signaling pathways, but the determinants of phosphatase specificity are poorly understood. This is because methods to investigate this at scale are lacking. Here, we develop ... -
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
(BMC, 2023-11-03)BACKGROUND: Ibrutinib, a first-in-class inhibitor of Bruton's tyrosine kinase, is approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. Based on encouraging preclinical data, ... -
Immunogenic cell death in cancer therapy
(Institute of Cancer Research (University Of London), 2024-01-16)Triple negative breast cancer (TNBC) is a heterogenous disease which carries a poor prognosis, with the worst outcomes in the basal-like subtype. Despite the introduction of immunotherapy in the treatment paradigm the ... -
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
(LIPPINCOTT WILLIAMS & WILKINS, 2024-01-01)PURPOSE: Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)-directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non-small-cell lung cancer. ... -
Inverse planning of lung radiotherapy with photon and proton beams using a discrete ordinates Boltzmann solver.
(IOP Publishing Ltd, 2024-02-02)Objective. A discrete ordinates Boltzmann solver has recently been developed for use as a fast and accurate dose engine for calculation of photon and proton beams. The purpose of this study is to apply the algorithm to the ... -
Recommendations for laboratory workflow that better support centralised amalgamation of genomic variant data: findings from CanVIG-UK national molecular laboratory survey.
(BMJ PUBLISHING GROUP, 2023-12-22)BACKGROUND: National and international amalgamation of genomic data offers opportunity for research and audit, including analyses enabling improved classification of variants of uncertain significance. Review of individual-level ... -
Cross-sectional analyses of online appointment booking and repeat prescription ordering user characteristics in general practices of England in the years 2018-2020.
(BMJ, 2023-10-12)OBJECTIVES: To explore the characteristics of the General Practice Patient Survey (GPPS) respondents using the different functionalities of the online services in the context of England's National Health Service General ... -
Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome.
(SPRINGERNATURE, 2023-11-01)BRCA1-associated protein-1 (BAP1) is a recognised tumour suppressor gene. Germline BAP1 pathogenic/likely pathogenic variants are associated with predisposition to multiple tumours, including uveal melanoma, malignant ... -
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
(BMJ PUBLISHING GROUP, 2023-08-07)OBJECTIVE: Olaparib plus bevacizumab maintenance therapy improves survival outcomes in women with newly diagnosed, advanced, high-grade ovarian cancer with a deficiency in homologous recombination. We report data from the ... -
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
(BMJ PUBLISHING GROUP, 2023-09-04)Compared with high-grade serous carcinoma, low-grade serous carcinoma of the ovary or peritoneum is a less frequent epithelial ovarian cancer type that is poorly sensitive to chemotherapy and affects younger women, many ... -
Quest markup for developing FAIR questionnaire modules for epidemiologic studies.
(BMC, 2023-10-25)BACKGROUND: Online questionnaires are commonly used to collect information from participants in epidemiological studies. This requires building questionnaires using machine-readable formats that can be delivered to study ... -
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
(ELSEVIER, 2023-11-01)BACKGROUND: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma. However, there is still a lack of head-to-head comparative ...